单位:[1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China[2]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China
Objective: Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modeling, drug discovery, and cell therapy development. In this review, we discuss the progress in applications of iIPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field. Data Sources: Articles in this review were searched from PubMed database from January 2014 to December 2017. Study Selection: Original articles about iPSCs and cardiovascular diseases were included and analyzed. Results: iIPSC holds great promises for human disease modeling, drug discovery, and stem cell-based therapy, and this potential is only beginning to be realized. However, several important issues remain to be addressed. Conclusions: The recent availability of human cardiomyocytes derived from iPSCs opens new opportunities to build in vitro models of cardiac disease, screening for new drugs and patient-specific cardiac therapy.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670275, 81670443]; China-Japan Friendship Hospital Youth Science and Technology Excellence Project [2015-QNYC-B-07]; International S and T Cooperation Program [2013DFA31900]
第一作者单位:[1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China[2]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China
通讯作者:
通讯机构:[1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China[2]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China[*1]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing 100029, China
推荐引用方式(GB/T 7714):
Feng Wang,Jie Kong,Yi‑Yao Cui,et al.Is Human-induced Pluripotent Stem Cell the Best Optimal?[J].CHINESE MEDICAL JOURNAL.2018,131(7):852-856.doi:10.4103/0366-6999.228231.
APA:
Feng Wang,Jie Kong,Yi‑Yao Cui,Peng Liu&Jian‑Yan Wen.(2018).Is Human-induced Pluripotent Stem Cell the Best Optimal?.CHINESE MEDICAL JOURNAL,131,(7)
MLA:
Feng Wang,et al."Is Human-induced Pluripotent Stem Cell the Best Optimal?".CHINESE MEDICAL JOURNAL 131..7(2018):852-856